GRIN2B

Researchers Discover a New Embryonic Brain Circuit

Retrieved on: 
Thursday, April 13, 2023
Cognition, Learning, Neuron, Hair, IOB, Autism spectrum, Spectrum, Allele, 3D, Embryo, Brain, Research, Temperature, Abdominal cavity, Movement, B cell, DSM-IV codes, Râșca, Cluj, Gene, GRIN2B, Vaccine, Cell

Basel, April 17, 2023 Using a new approach for studying live embryonic mouse brains at single-cell resolution, researchers have identified an active multi-layer circuit that forms in the cortex during an unexpectedly early stage of development.

Key Points: 
  • Basel, April 17, 2023 Using a new approach for studying live embryonic mouse brains at single-cell resolution, researchers have identified an active multi-layer circuit that forms in the cortex during an unexpectedly early stage of development.
  • Perturbing the circuit genetically led to changes similar to those seen in the brains of people with autism.
  • The findings are reported today in Cell by a team based at the Institute of Molecular and Clinical Ophthalmology Basel.
  • In future research, IOB researchers will "carefully look at the superficial and deep layers of this early circuitry and independently manipulate them," Roska says.

GRIN Therapeutics Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for Treatment of GRIN-related Disorders

Retrieved on: 
Thursday, March 23, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Epilepsy, Seizure, Maintenance, Rapid eye movement sleep behavior disorder, GOF, DSM-IV codes, Sleep, GRIN, Pharmacokinetics, NMDA, Honeycomb, Research, GRIN1, Intellectual disability, Human genetics, NR2B, Genetics, Patient, Spectrum, MPH, Therapy, Gene, Safety, SLC6A1 epileptic encephalopathy, Pharmaceutical industry, GRIN2B, GRIN2A, GRIN2D

GRIN Therapeutics Inc., a leader in development of therapies to treat GRIN-related disorders, today announced that the first patient has been dosed in the Honeycomb Study, the Company’s Phase 1B clinical trial of radiprodil, an investigational NR2B-negative allosteric modulator in development for the treatment of GRIN-related disorders.

Key Points: 
  • GRIN Therapeutics Inc., a leader in development of therapies to treat GRIN-related disorders, today announced that the first patient has been dosed in the Honeycomb Study, the Company’s Phase 1B clinical trial of radiprodil, an investigational NR2B-negative allosteric modulator in development for the treatment of GRIN-related disorders.
  • Radiprodil targets the hyperactive receptors associated with the development and progression of GRIN-related disorders by potently and selectively modulating the Nmethyl-D-aspartate (NMDA) receptor subtype 2B (NR2B).
  • People living with GRIN-related disorders present with a spectrum of symptoms including epilepsy, behavioral disorders, autism, intellectual disability, and movement disorders.
  • Currently, there are no disease-specific treatment options for GRIN-related disorders.

MIJ 821: Developed by Novartis for Treatment Resistant Depression - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 11, 2021
Pharmaceutical, Health, Clinical trials, Branches of biology, Ionotropic glutamate receptors, Life sciences, Biology, NMDA receptor antagonists, GRIN2B, Major depressive disorder, Novartis, NMDA receptor, Mij, Treatment-resistant depression

MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treatment Resistant Depression.

Key Points: 
  • MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treatment Resistant Depression.
  • "MIJ 821 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Treatment Resistant Depression in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Other emerging products for Treatment Resistant Depression are giving market competition to MIJ 821 and launch of late-stage emerging therapies in the near future will significantly impact the market.

Stratosphere Networks Donates to Bee Active Campaign for GRIN2B Foundation

Retrieved on: 
Thursday, September 24, 2020
Las Vegas Valley, Ionotropic glutamate receptors, Cision, GRIN2B, The Strat

CHICAGO, Sept. 24, 2020 /PRNewswire-PRWeb/ -- Stratosphere Networks , a Chicago-based managed services provider, has donated to the Bee Active fundraising campaign for GRIN2B Foundation , a parent-run organization committed to furthering research on the GRIN2B gene and supporting individuals and families affected by a GRIN2B diagnosis.

Key Points: 
  • CHICAGO, Sept. 24, 2020 /PRNewswire-PRWeb/ -- Stratosphere Networks , a Chicago-based managed services provider, has donated to the Bee Active fundraising campaign for GRIN2B Foundation , a parent-run organization committed to furthering research on the GRIN2B gene and supporting individuals and families affected by a GRIN2B diagnosis.
  • Bee Active for GRIN2B is a free virtual fitness event that encourages supporters to pick an activity and date to participate any time during the month of September.
  • "We're happy to show our support for GRIN2B Foundation by contributing to Bee Active," said Kevin Rubin, president and CIO of Stratosphere Networks.
  • Stratosphere Networks has an ongoing relationship with GRIN2B Foundation and sponsored the organization's first cocktail reception fundraiser in 2019, in addition to their first family conference in Atlanta in 2018.

Horizon Photography to Provide Official Event Photos of First GRIN2B Foundation Fundraiser

Retrieved on: 
Thursday, September 26, 2019
Ionotropic glutamate receptors, GRIN2B

EVANSTON, Ill., Sept. 26, 2019 /PRNewswire-PRWeb/ -- Horizon Photography will provide the official event photos of Gather for GRIN2B , GRIN2B Foundation's first cocktail reception fundraiser.

Key Points: 
  • EVANSTON, Ill., Sept. 26, 2019 /PRNewswire-PRWeb/ -- Horizon Photography will provide the official event photos of Gather for GRIN2B , GRIN2B Foundation's first cocktail reception fundraiser.
  • Proceeds will go toward funding research on GRIN2B-Related Neurodevelopmental Disorder, a rare condition caused by variations on the GRIN2B gene.
  • "I'm really looking forward to helping get the word out about GRIN2B Foundation's first cocktail reception fundraiser," said Jennifer Schuman, owner of Horizon Photography.
  • Horizon Photography is a boutique Evanston-based photo studio focused on providing creative content and assisting with personal branding.

Stratosphere Networks to Sponsor GRIN2B Foundation's First Cocktail Reception Fundraiser

Retrieved on: 
Thursday, September 12, 2019
Ionotropic glutamate receptors, GRIN2B, Las Vegas Valley, Stratosphere, Nevada

CHICAGO, Sept. 12, 2019 /PRNewswire-PRWeb/ -- Stratosphere Networks will sponsor GRIN2B Foundation's first cocktail reception fundraiser, Gather for GRIN2B .

Key Points: 
  • CHICAGO, Sept. 12, 2019 /PRNewswire-PRWeb/ -- Stratosphere Networks will sponsor GRIN2B Foundation's first cocktail reception fundraiser, Gather for GRIN2B .
  • "We're proud to be one of the sponsors of GRIN2B Foundation's first cocktail benefit," said Kevin Rubin, president and CIO of Stratosphere Networks.
  • Stratosphere Networks has an ongoing relationship with GRIN2B Foundation, which is a parent-run organization dedicated to providing support for those affected by GRIN2B variations and furthering research on the GRIN2B gene.
  • Since 2003, Stratosphere Networks has grown exponentially and continues to provide the best-in-class and cost-effective solutions to businesses in all industries.

Cadent Therapeutics Receives Milestone Payment for Initiation of Phase 2 Trial of MIJ821 in Treatment-Resistant Depression

Retrieved on: 
Thursday, May 23, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Branches of biology, Neurological disorders, Ionotropic glutamate receptors, Organ systems, Glutamate, Cell signaling, Molecular neuroscience, NMDA receptor, Cadent, GRIN2B, Spinocerebellar ataxia, Ataxia

"We are excited to announce thatNovartishas advanced MIJ821 to the next stage of clinical development, said Jodie Morrison, Chief Executive Officer of Cadent Therapeutics.

Key Points: 
  • "We are excited to announce thatNovartishas advanced MIJ821 to the next stage of clinical development, said Jodie Morrison, Chief Executive Officer of Cadent Therapeutics.
  • Cadent Therapeutics exclusively licensed the intellectual property for compounds that selectively modulate NR2B-containing NMDA receptors to Novartis.
  • Cadent Therapeutics is creating therapies for the treatment of movement disorders and cognitive impairment.
  • Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor and schizophrenia.

Stratosphere Networks Sponsors 2018 GRIN2B Foundation Family Conference

Retrieved on: 
Thursday, September 6, 2018
Ionotropic glutamate receptors, GRIN2B

CHICAGO, Sept. 6, 2018 /PRNewswire-PRWeb/ -- Stratosphere Networks has announced it will sponsor the GRIN2B Foundation's first Family Conference in Atlanta, Georgia on Friday, September 21 and Saturday, September 22.

Key Points: 
  • CHICAGO, Sept. 6, 2018 /PRNewswire-PRWeb/ -- Stratosphere Networks has announced it will sponsor the GRIN2B Foundation's first Family Conference in Atlanta, Georgia on Friday, September 21 and Saturday, September 22.
  • The GRIN2B Foundation is a parent-run organization devoted to furthering GRIN2B gene research and supporting the growing community of people impacted by a GRIN2B diagnosis.
  • GRIN2B is a gene on the short arm of the 12th chromosome and is one member of a family of 7 genes, according to the Foundation .
  • For more information about the GRIN2B Foundation Family Conference, please visit the GRIN2B Foundation website .